Short answer
Aurinia Pharmaceuticals Inc. (AUPH) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $78M (up 24.4% year over year) with net income of $34M.
Q1 2026 key financials · XBRL
- Revenue
- $78M
- +24.4% YoY
- Net income
- $34M
- +47.2% YoY
- Operating margin
- 53.3%
- EPS (diluted)
- $0.25
- +56.3% YoY
Source: XBRL data from the Aurinia Pharmaceuticals Inc. (AUPH) Q1 2026 10-Q on SEC EDGAR. USD.
Aurinia Pharmaceuticals Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $77.7M, up $15.2M YoY from $62.5M
- LUPKYNIS sales $73.6M, up 23% from $60.0M
- Gross margin 92% vs 86% YoY; net income $34.4M vs $23.3M
- Cash $378.8M vs $398.0M; operating cash flow $32.6M vs $1.3M
- Share repurchases $36.2M; R&D expected to increase as development activities progress
Risk Factors
- No risk-factors section provided; filing excerpt contains no 10-Q versus 10-K risk-factor comparison
- Management transition risk triggered by four executive departures effective March 20, 2026
- Operational continuity risk from former executives serving as consultants only through June 20, 2026
- Capital-allocation risk from $211.0 million cumulative share repurchases and $125.3 million remaining authorization
- Governance risk from Peter Greenleaf’s resignation as director effective March 21, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aurinia Pharmaceuticals Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.